Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Moleculin Biotech Misses Fiscal Q2 EPS

TheMotleyFool

0 0

Moleculin Biotech (NASDAQ:MBRX), a clinical-stage pharmaceutical developer focused on oncology, released its second quarter 2025 results on August 13, 2025.

The biggest news from this update was a GAAP net loss of $(7.6) million.

Reported GAAP EPS of $(0.49) missed the analyst estimate of $(0.40), falling short by $0.09 or 22.3%. As expected, there was no revenue. The overall quarter brought expanded clinical activity and important regulatory developments, but it also highlighted the company’s growing reliance on external funding and balance sheet pressures.

Source Fool.com